NOTCH1 and B-cell chronic lymphocytic leukemia: CLL patients with NOTCH1 mutations do not benefit from rituximab-combining therapies, which may be related to lower levels of CD20 expression in NOTCH1 mutated cases [30,31], while a longer progression-free survival was demonstrated when treated with alemtuzumab [32].